Acromegaly and pregnancy - 25/08/11
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Résumé |
Chez les patientes ayant un adénome somatotrope responsable d’une acromégalie, la survenue d’une grossesse impose d’envisager : (1) les conséquences de la grossesse sur l’adénome hypophysaire et les sécrétions de growth hormone (GH) et d’IGF-1, (2) les conséquences de l’hypersécrétion somatotrope (GH/IGF-1) pour la mère et le fœtus, (3) les conséquences du traitement chirurgical ou médical (agonistes dopaminergiques, analogues de la somatostatine, antagoniste du récepteur de la GH) chez la mère et le développement du fœtus.
Il testo completo di questo articolo è disponibile in PDF.Abstract |
In women with acromegaly due to growth hormone (GH)-secreting pituitary adenomas, the occurrence of pregnancy warrants consideration of: (1) the consequences of pregnancy on the pituitary adenoma including the tumor syndrome and GH/IGF-1 secretion, (2) the consequence of GH/IGF-1 hypersecretion on the pregnant woman and the fetus, (3) the consequences of pituitary surgery and medical treatment (dopamine agonists, somatostatin analogs, GH receptor antagonist) on the pregnant woman and the developing fetus.
Il testo completo di questo articolo è disponibile in PDF.Mappa
Vol 72 - N° 4
P. 282-286 - settembre 2011 Ritorno al numero
Articolo precedente
- Guidelines of the French society of endocrinology for the management of thyroid nodules
- J.-L. Wémeau, J.-L. Sadoul, M. d’Herbomez, H. Monpeyssen, J. Tramalloni, E. Leteurtre, F. Borson-Chazot, P. Caron, B. Carnaille, J. Léger, C. Do, M. Klein, I. Raingeard, R. Desailloud, L. Leenhardt
- Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: Predictive factors of the treatment response in type 2 diabetes
- J.-F. Gautier, J.-P. Sauvanet
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.